Last updated: 2026-10-14 12:37:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Avita Medical, Inc. (RCEL) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $13.20, with a market capitalisation of $413.49M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.22 to $13.73. This page covers its latest market performance, valuation, price trends and company information.
$413.49M | |
$13.25 | |
$30.78 | |
$3.22 | |
$13.36 | |
54.00 | |
446.80K | |
-- | |
$13.73 | |
$3.22 | |
-- | |
-- |
Avita Medical, Inc. (RCEL) is trading at $13.20 in pre-market trading as of 2026-10-14 12:33:00, down 1.23% ($0.16) from the previous close of $13.36
Pre-market trading shows how investors are pricing RCEL before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Avita Medical, Inc. (RCEL) moved from $13.25 to $13.20, representing a decline of 0.41% ($0.05).
The stock traded between $12.39 and $13.73 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 334.21 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 94.9%
RCEL is currently trading at $13.20, placing it 94.9% of the way from its 52-week low of $3.22 to its 52-week high of $13.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 226 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Avita Medical, Inc. (RCEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.